Fig. 1From: The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis planConsolidated Standards of Reporting Trials (CONSORT) trial flow chart for the Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT)Back to article page